English, Article edition: Threshold Analysis of Helicobacter pylori Therapy Amnon Sonnenberg

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94399
Physical Description
  • article
Language
  • English

Edition details

Title
  • Threshold Analysis of Helicobacter pylori Therapy
Author
  • Amnon Sonnenberg
Physical Description
  • article
Notes
  • Objective: Conflicting recommendations have been made on whom to treat with antibacterials to eradicate Helicobacter pylori . The present analysis aims to explain the basis of such discrepancies. Design and Setting: The decision in favour of or against antibacterial therapy in patients with upper gastrointestinal symptoms is modelled as a threshold analysis. The threshold is the lowest probability for a given diagnosis at which the decision in favour of antibacterial therapy yields a higher expected outcome than the decision against it. A strong indication for antibacterial therapy is shown by a low threshold value. Main Outcome Measures and Results: In patients with suspected peptic ulcer disease, both the high success rate of antibacterial therapy and its low cost make it the most favourable treatment option, its threshold being less than 35%. In ulcer patients receiving nonsteroidal anti-inflammatory drugs, the threshold is 73% if based on success rates of different treatment modalities, but only 7% if treatment costs are considered. The relatively poor success rate of antibacterial therapy in non-ulcer dyspepsia raises the diagnostic threshold for antibacterial therapy to 76% if based on therapeutic success rates. The small marginal cost of antibacterial therapy lowers the diagnostic threshold to 16%. Conclusion: If therapeutic success is the primary concern, patients with vague abdominal symptoms should not be given antibacterial therapy, unless H. pylori has been established as a probable cause of their symptoms. If healthcare costs are the driving force for choosing one type of therapy over another, a trial of antibacterials appears indicated irrespective of any firm validation of H. pylori playing a role in the patient's disease.
  • Pharmacoeconomics, Antibacterials, Peptic-ulcer, Helicobacter-pylori-infections, Cost-analysis, Clinical-trial-design
  • RePEc:wkh:phecon:v:14:y:1998:i:4:p:423-432
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment